Robin Fabre
Internal Medicine · Franklinton, LANPI 1366416935
Payments from drug & device makers
Across 306 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$622
- Lilly USA, LLC$574
- AstraZeneca$285
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$244
- GSK$196
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,769100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 94 | $1,163 |
| Novo Nordisk | 42 | $622 |
| Lilly USA, LLC | 41 | $574 |
| AstraZeneca | 12 | $285 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $244 |
| GSK | 11 | $196 |
| Astellas Pharma US Inc | 10 | $184 |
| Pharmacosmos Therapeutics Inc. | 4 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $121 |
| Boehringer Ingelheim | 6 | $94 |
| Daiichi Sankyo Inc. | 5 | $89 |
| Dexcom, Inc. | 4 | $78 |
| Pfizer | 4 | $73 |
| Sumitomo Pharma America, Inc. | 5 | $73 |
| Abbott | 4 | $70 |
| Optinose US, Inc. | 4 | $63 |
| Merck | 4 | $60 |
| Exact Sciences | 3 | $54 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| Amgen | 3 | $43 |
| Esperion Therapeutics, Inc. | 3 | $38 |
| Corcept Therapeutics | 2 | $36 |
| Sanofi Pasteur Inc. | 2 | $34 |
| Shield Therapeutics Inc | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Bayer | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
| Nevro Corp. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$100
How this compares
$4,769 in reported general payments places this provider in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 83 | $103,546 |
| TrulicityDulaglutide | 66 | $94,221 |
| RybelsusSemaglutide | 75 | $90,081 |
| OzempicSemaglutide | 67 | $84,899 |
| JardianceEmpagliflozin | 42 | $48,997 |
| TradjentaLinagliptin | 28 | $25,873 |
| FarxigaDapagliflozin Propanediol | 36 | $22,679 |
| EliquisApixaban | 32 | $22,088 |
| JanuviaSitagliptin Phosphate | 21 | $19,240 |
| XareltoRivaroxaban | 32 | $17,453 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $13,080 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $10,813 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $7,653 |
| LinzessLinaclotide | 13 | $6,792 |
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $6,299 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $574 | $197,766149 claims |
| Novo NordiskRybelsus, Ozempic | $622 | $174,981142 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $94 | $80,64582 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix | $196 | $28,18353 claims |
| AstraZenecaFarxiga | $285 | $22,67936 claims |
| PfizerEliquis | $73 | $22,08832 claims |
| MerckJanuvia | $60 | $19,24021 claims |
| Johnson & JohnsonXarelto | $13 | $17,45332 claims |
| AbbVieLinzess, Synthroid | $1,163 | $9,75358 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $3,686478 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Franklinton
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
- Satinder SainiCrowley$1.8M
- Randall MillerEunice$1.2M
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.